LOGISTICS-

The Red Sea Ports Authority is mulling awarding the EGP 4 bn Taba Port development project to Suez Canal Authority’s subsidiary Suez Canal Ports Company, unnamed government sources told Al Borsa. The port is slated to give local exports access to new markets at lower costs and ease the reliance on traditional land routes by opening up faster and more efficient access to Jordan and Saudi Arabia.

M&A-

Restructuring at cosmetics pharma giant Macro Group (Macro Capital) turned its major shareholders into direct shareholders, after having originally held their stakes through the special purpose investment vehicle Leo1 prior to the restructuring of the group's ownership and shareholding structure, according to an EGX disclosure (pdf). Our friends at EFG Hermes International Securities Brokerage executed the transaction.

RESTORATION-

Property developer Madinet Masr is launching a heritage restoration project in Historic Cairo, the company said in a statement(pdf). Under the name Buyut Al-Khalifa, the initiative is being developed in partnership with the Built Environment Collective and with the backing of the Supreme Council of Antiquities. the project will focus on reviving the urban fabric of Al Rukbiyya Street and rehabilitating the area’s historic buildings and public spaces using eco-friendly materials and sustainable construction methods. The developer will break ground on the project next month, with implementation set to span three years.

What they said: “Community engagement is a cornerstone of our identity and vision. We are proud to take part in developing the Buyut Al Khalifa project, which seeks to revive endangered urban sites, especially in archaeological and heritage areas,” said CEO Abdallah Sallam.

HEALTHCARE-

Egypt is exploring a proposal with UK-based pharma giant GSK to establish the Middle East and North Africa’s first Multi Omics research center, according to a Health Ministry statement. The proposed facility would specialize in analyzing biological markers in oncology to tailor treatments based on individual patient responses, with additional research applications in liver disease, neurological disorders, and respiratory infections. The two sides also discussed project financing, implementation timelines, and operating models — details of which, the statement didn’t disclose.

Tags: